761 related articles for article (PubMed ID: 28991932)
21. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Johansen P; Sandberg A; Capehorn M
Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
[TBL] [Abstract][Full Text] [Related]
22. Once-weekly glucagon-like peptide 1 receptor agonists.
Kalra S; Gupta Y
J Pak Med Assoc; 2015 Jul; 65(7):796-8. PubMed ID: 26160096
[TBL] [Abstract][Full Text] [Related]
23. Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.
Rivera FB; Lumbang GNO; Gaid DRM; Cruz LLA; Magalong JV; Bantayan NRB; Lara-Breitinger KM; Gulati M; Bakris G
Diabetes Obes Metab; 2024 Jun; 26(6):2209-2228. PubMed ID: 38505997
[TBL] [Abstract][Full Text] [Related]
24. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
Triplitt C; Solis-Herrera C
Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
[TBL] [Abstract][Full Text] [Related]
25. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
Chun JH; Butts A
JAAPA; 2020 Aug; 33(8):3-18. PubMed ID: 32740121
[TBL] [Abstract][Full Text] [Related]
26. [Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].
Li ZX; Wu SS; Yang ZR; Zhan SY; Sun F
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Jun; 48(3):454-9. PubMed ID: 27318907
[TBL] [Abstract][Full Text] [Related]
27. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
Urquhart S; Willis S
JAAPA; 2020 Aug; 33(8):19-30. PubMed ID: 32740122
[TBL] [Abstract][Full Text] [Related]
28. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
[TBL] [Abstract][Full Text] [Related]
29. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Nauck MA; Frossard JL; Barkin JS; Anglin G; Hensley IE; Harper KD; Milicevic Z
Diabetes Care; 2017 May; 40(5):647-654. PubMed ID: 28283565
[TBL] [Abstract][Full Text] [Related]
30. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States.
Mody R; Huang Q; Yu M; Zhao R; Patel H; Grabner M; Landó LF
Diabetes Obes Metab; 2019 Apr; 21(4):920-929. PubMed ID: 30520248
[TBL] [Abstract][Full Text] [Related]
31. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
Madsbad S
Diabetes Obes Metab; 2016 Apr; 18(4):317-32. PubMed ID: 26511102
[TBL] [Abstract][Full Text] [Related]
32. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes.
Unni S; Wittbrodt E; Ma J; Schauerhamer M; Hurd J; Ruiz-Negrón N; McAdam-Marx C
Diabetes Obes Metab; 2018 Feb; 20(2):468-473. PubMed ID: 28862808
[TBL] [Abstract][Full Text] [Related]
33. Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis.
Weeda ER; Muraoka AK; Brock MD; Cannon JM
Int J Clin Pract; 2021 Sep; 75(9):e14060. PubMed ID: 33527605
[TBL] [Abstract][Full Text] [Related]
34. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
Urquhart S; Willis S
JAAPA; 2020 Aug; 33(S8 Suppl 1):19-30. PubMed ID: 32756221
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
36. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.
Milicevic Z; Anglin G; Harper K; Konrad RJ; Skrivanek Z; Glaesner W; Karanikas CA; Mace K
Diabetes Obes Metab; 2016 May; 18(5):533-6. PubMed ID: 26847401
[TBL] [Abstract][Full Text] [Related]
37. [Dulaglutide and liraglutide compared].
Bruhn C
Med Monatsschr Pharm; 2015 May; 38(5):198-9. PubMed ID: 26364414
[No Abstract] [Full Text] [Related]
38. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
Nguyen H; Dufour R; Caldwell-Tarr A
Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
[TBL] [Abstract][Full Text] [Related]
39. Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.
Tanaka K; Okada Y; Tokutsu A; Tanaka Y
Sci Rep; 2022 Jan; 12(1):154. PubMed ID: 34997102
[TBL] [Abstract][Full Text] [Related]
40. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
